SCHEMBL7750852

SCHEMBL7750852

CCCC(=O)Nc1ccccc1CC

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.71
HDAC4 P56524 1/20 0.71
HDAC1 Q13547 1/20 0.71
HDAC7 Q8WUI4 1/20 0.71
HDAC2 Q92769 1/20 0.71
HDAC10 Q969S8 1/20 0.71
HDAC11 Q96DB2 1/20 0.71
HDAC8 Q9BY41 1/20 0.71
HDAC6 Q9UBN7 1/20 0.71
HDAC9 Q9UKV0 1/20 0.71
HDAC5 Q9UQL6 1/20 0.71
MAPK1 P28482 1/20 0.69
HTT P42858 1/20 0.59
POLB P06746 3/20 0.57
GRK2 P25098 2/20 0.57
TAS1R3 Q7RTX0 1/20 0.55
TAS1R1 Q7RTX1 1/20 0.55
KMT2A Q03164 2/20 0.55
PPARG P37231 1/20 0.55
CTDSP1 Q9GZU7 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26645943 0.89 HDAC3 (0.77) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7482482 0.88 MAPK1 (0.63) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL14351015 0.88 MAPK1 (0.63) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL27910330 0.88 MAPK1 (0.63) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9312836 0.86 HDAC3 (0.67) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL23229080 0.86 MAPK1 (0.61) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL29195205 0.86 HDAC3 (0.77) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL14426830 0.86 HDAC3 (0.67) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL19364615 0.85 MAPK1 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3034142 0.85 MAPK1 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024008196-A1 CLASS OF AMIDE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 中国科学院上海药物研究所 2024-01-11 WO disclosed
US-20110229581-A1 RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS ENZON PHARMACEUTICALS, INC. (US) 2011-09-22 US disclosed
US-20110223257-A1 RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS ENZON PHARMACEUTICALS, INC. (US) 2011-09-15 US disclosed
EP-0505378-B1 DELIVERY SYSTEM FOR AGRICULTURAL CHEMICALS ISP INVESTMENTS INC (US) 2001-01-03 EP disclosed
EP-0574492-B1 STABILIZATION OF MICROEMULSIONS USING HYDROPHOBIC ACID BUFFERS ISP INVESTMENTS INC (US) 1999-05-12 EP disclosed
EP-0701398-A4 INERT MATRIX COMPOSITION, PREPARATION THEREOF AND MICROEMULSIFIABLE CONCENTRATE ISP INVESTMENTS INC (US) 1998-01-07 EP disclosed
EP-0707444-A1 STABLE EMULSIFIABLE GEL MATRIX FOR FORMING GEL CONCENTRATE WITH AGRICULTURAL CHEMICAL, AND AQUEOUS MACROEMULSION THEREFROM ISP INVESTMENTS INC. (US) 1996-04-24 EP disclosed
EP-0701398-A1 INERT MATRIX COMPOSITION, PREPARATION THEREOF AND MICROEMULSIFIABLE CONCENTRATE ISP INVESTMENTS INC. (US) 1996-03-20 EP disclosed
WO-1995001723-A1 STABLE EMULSIFIABLE GEL MATRIX FOR FORMING GEL CONCENTRATE WITH AGRICULTURAL CHEMICAL, AND AQUEOUS MACROEMULSION THEREFROM ISP INVESTMENTS INC. (US) 1995-01-19 WO disclosed
WO-1994028711-A1 INERT MATRIX COMPOSITION, PREPARATION THEREOF AND MICROEMULSIFIABLE CONCENTRATE ISP INVESTMENTS INC. (US) 1994-12-22 WO disclosed
EP-0574492-A4 STABILIZATION OF MICROEMULSIONS USING HYDROPHOBIC ACID BUFFERS. ISP INVESTMENTS INC (US) 1994-03-17 EP disclosed
EP-0574492-A1 STABILIZATION OF MICROEMULSIONS USING HYDROPHOBIC ACID BUFFERS ISP INVESTMENTS INC. (US) 1993-12-22 EP disclosed
WO-1992013454-A1 STABILIZATION OF MICROEMULSIONS USING HYDROPHOBIC ACID BUFFERS ISP INVESTMENTS INC. (US) 1992-08-20 WO disclosed
EP-0179118-B1 HERBICIDAL COMPOSITIONS WITH PROLONGED ACTION AND IMPROVED SELECTIVITY NITROKEMIA IPARTELEPEK (HU) 1989-03-15 EP disclosed
EP-0083613-B1 N-PHENYLPYRAZOLE DERIVATIVES USEFUL AS HERBICIDES MAY & BAKER LIMITED (GB) 1988-06-01 EP disclosed
EP-0084033-B1 N-PHENYLPYRAZOLE DERIVATIVES MAY & BAKER LIMITED (GB) 1985-10-02 EP disclosed
EP-0053011-B1 NEW HERBICIDAL NICOTINAMIDE DERIVATIVES MAY & BAKER LIMITED (GB) 1985-04-03 EP disclosed
US-3962307-A HERBICIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110229581-A1 RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS APLNR, LPAR6, ABHD16A HDAC3 862/4885HDAC4 1821/4885HDAC1 1101/4885
US-20110223257-A1 RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS FUS, HNRNPUL2, HNRNPDL HDAC3 2895/4885HDAC4 2927/4885HDAC1 3641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.